Qiagen Is Next Candidate for Health-Care Tax Deal Wave: Real M&A

Qiagen NV investors are betting the busiest year for health-care deals in more than a decade will lure acquirers to one of the industry’s most expensive targets.

Shares of the maker of diagnostic tools to tailor medical treatments have climbed three times as much as peers since June